BIOMAT Database Logo BIOMAT Database Logo

Identification of a pharmacophore for nucleoside analog inhibitors directed at HIV-1 reverse transcriptase. 1994

M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
Department Biochemistry and Molecular Biology, UMDNJ New Jersey Medical School, Newark 07103.

An 'active analog' approach to receptor mapping was used to identify a pharmacophore for a set of thymidine nucleoside analog inhibitors of HIV-1 reverse transcriptase. The preliminary results indicate that the O2, O4', and O5' atoms are capable of adopting a unique pharmacophoric pattern which may be the key to their recognition by reverse transcriptase.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D003196 Computer Graphics The process of pictorial communication, between human and computers, in which the computer input and output have the form of charts, drawings, or other appropriate pictorial representation. Computer Graphic,Graphic, Computer,Graphics, Computer
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
HIV nucleoside reverse transcriptase inhibitors.
October 2022, European journal of medicinal chemistry,
M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase.
September 2006, Bioorganic & medicinal chemistry,
M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
March 2020, Bioorganic chemistry,
M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors.
April 1998, Antiviral research,
M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.
April 2003, AIDS (London, England),
M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.
December 2013, Future medicinal chemistry,
M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
Search for new non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-1 RT).
January 2002, Acta poloniae pharmaceutica,
M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.
February 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,
M A Fisher, and P N Yadav, and J Yadav, and D Kristol, and E Arnold, and M J Modak
Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors.
January 2007, Journal of chemical information and modeling,
Copied contents to your clipboard!